Radiotherapy improves survival after breast-conserving surgery

January 20, 2004

The omission of radiotherapy after breast-conserving surgery for early-stage breast cancer is associated with higher rates of relapse and a slightly higher mortality rate, according to a study in the January 21 issue of the Journal of the National Cancer Institute.

Many studies have shown that women with early-stage breast cancer who have breast-conserving surgery followed by radiotherapy have similar survival rates as women who have a mastectomy, and those women are also spared the disfiguration of losing their breast. However, radiotherapy prolongs the length of time that women are treated for breast cancer, the treatment can be costly, radiotherapy facilities are not common in all areas, and there are some side effects to radiotherapy.

For these reasons, several studies have examined the consequences of omitting radiotherapy from the treatment regimen. Vincent Vinh-Hung, M.D., of the Oncology Center at Academic Hospital in Jette, Belgium, and colleagues performed a pooled analysis of 15 randomized clinical trials of women with early-stage breast cancer who underwent breast-conserving surgery alone or surgery followed by radiotherapy. They analyzed recurrence rates based on information from 9,422 women, and mortality information was available for 8,206 women.

The authors calculated that the women who received breast-conserving surgery alone were three times more likely to have a relapse than women who had breast-conserving surgery followed by radiotherapy. (In clinical trials that had 5 or more years of follow-up information, the relapse rate ranged from 0.4% to 2.1% per year for women who received breast-conserving surgery and radiotherapy, compared with 1.4% to 5.7% per year among women who only had surgery.) The authors also calculated that the omission of radiotherapy resulted in an 8.6% relative excess of deaths.

"The present study confirms that radiotherapy should not be omitted after breast-conserving surgery, except for medical contraindications such as systemic vascular disease or a previous history of irradiation," the authors conclude.

In an editorial, Katherine A. Vallis, M.D., Ph.D., and Ian F. Tannock, M.D., Ph.D., of Princess Margaret Hospital, Toronto, note that, although there may be a small subset of women with good prognostic factors who do not need to have radiotherapy after surgery, this analysis "reinforces the view that the large majority of patients undergoing breast-conserving surgery should also receive radiotherapy."
-end-
Contacts:
  • Claire Verschraegen, University of New Mexico Cancer Research and Treatment Center, Albuquerque, 505-272-6760, cverschraegen@salud.unm.edu; Vincent Vinh-Hung, Oncology Center at Academic Hospital, Jette, Belgium, 32-2-477-6041, conrvhgv@az.vub.ac.be
  • Editorial: Vince Rice, Princess Margaret Hospital, 416-946-4501, ext. 5771; vince.rice@uhn.on.ca

    Citations:
  • Vinh-Hung V, Verschraegen C, for the Breast Conserving Surgery Project. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 2004;96:115-21.
  • Vallis KA, Tannock IF. Postoperative radiotherapy for breast cancer: growing evidence for an impact on survival. J Natl Cancer Inst 2004;96:88-9.

    Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oupjournals.org/.

    Journal of the National Cancer Institute

    Related Breast Cancer Articles from Brightsurf:

    Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
    The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

    Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
    New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

    Partial breast irradiation effective treatment option for low-risk breast cancer
    Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

    Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
    Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

    More clues revealed in link between normal breast changes and invasive breast cancer
    A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

    Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
    A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

    Computers equal radiologists in assessing breast density and associated breast cancer risk
    Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

    Blood test can effectively rule out breast cancer, regardless of breast density
    A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

    Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
    Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

    Young breast cancer patients undergoing breast conserving surgery see improved prognosis
    A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

    Read More: Breast Cancer News and Breast Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.